Agios Pharmaceuticals

Agios Pharmaceutical Inc.
Public
Traded as NASDAQ: AGIO
Russell 1000 Component
Industry Pharmaceuticals
Founded 2008 (2008)
Headquarters Cambridge, Massachusetts, United States
Key people
 David Schenkein (CEO)
Website agios.com
Footnotes / references
Foundation[1]

Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.[1][2] Among the proteins under investigation by the company are IDH1 and IDH2.[3] The company was founded in 2008 (or 2007)[3] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[1][4] The company tendered an initial public offering in July 2013.[5]:Table 1

History

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.[3]

In May 2016, the company announced it would launch partnership with Celgene,[6] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.[7]

In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.[8]

In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or R/R AML with an IDH1 mutation.[9]

Corporate governance

As of April 2017, Agios' CEO was David Schenkein.[8]

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.[3][5]

References

  1. 1 2 3 Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
  2. ↑ Anton, Ted (2013). "Chapter 13". The Longevity Seekers (Google eBook). University of Chicago Press. p. 163. ISBN 9780226020938.
  3. 1 2 3 4 Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.
  4. ↑ "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
  5. 1 2 Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
  6. ↑ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN.
  7. ↑ Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
  8. 1 2 "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
  9. ↑ Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.

Notes


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.